无水滴眼环孢素0.1%溶液治疗中重度干眼病的疗效与安全性:ESSENCE-2随机临床试验
ESSENCE-2是一项3期多中心随机双盲载体对照研究,共纳入834例中重度干眼病患者,随机接受无水滴眼环孢素0.1%溶液或载体每日两次治疗29天。结果显示环孢素组总角膜荧光素染色较载体组有改善,且达到临床意义应答者比例更高,但干涩症状评分两组无显著差异。
要点
- 环孢素组第29天总角膜荧光素染色改善-4.0级,载体组为-3.6级,组间差异有统计学意义。
- 环孢素组71.6%达到总角膜荧光素染色改善≥3级的临床意义应答,载体组为59.7%。
- 干涩症状评分两组均改善,但组间差异无统计学意义。
核心结论
- ESSENCE-2试验证实无水滴眼环孢素0.1%溶液较载体在眼表产生早期治疗效应。
- 应答者分析提示该效应在环孢素组71.6%的受试者中具有临床意义。
研究设计与样本
- 3期多中心随机双盲载体对照临床研究,于2020年12月5日至2021年10月8日进行。
- 纳入中重度干眼病患者,经14天人工泪液每日两次导入期后按1:1随机分组。
- 共834例受试者随机分配至环孢素组423例(50.7%)或载体组411例(49.3%),来自27个研究中心。
- 干预为环孢素溶液或载体每日两次给药29天。
主要发现
- 受试者平均(SD)年龄57.1(15.8)岁,女性609例(73.0%)。
- 第29天总角膜荧光素染色变化:环孢素组-4.0级 vs 载体组-3.6级,变化差值-0.4(95%CI,-0.8至0;P=0.03)。
- 第29天干涩评分变化:环孢素组-12.2分 vs 载体组-13.6分,差值1.4(95%CI,-1.8至4.6;P=0.38)。
- 总角膜荧光素染色改善≥3级的应答者比例:环孢素组293例(71.6%) vs 载体组236例(59.7%),差值12.6%(95%CI,6.0%-19.3%;P<0.001)。
- 应答者第29天症状改善优于非应答者:干涩差值-4.6(95%CI,-8.0至-1.2;P=0.007),视物模糊差值-3.5(95%CI,-6.6至-4.0;P=0.03)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Dry eye disease (DED) is a common public health problem with significant impact on vision-related quality of life and well-being of patients. Medications with rapid onset of action and a good tolerability profile remain an unmet need. OBJECTIVE: To assess efficacy, safety, and tolerability of a water-free cyclosporine ophthalmic solution, 0.1% (CyclASol [Novaliq GmbH]), applied twice daily in DED compared with vehicle. DESIGN, SETTING, AND PARTICIPANTS: CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (ESSENCE-2) was a phase 3, multicenter, randomized, double-masked, vehicle-controlled clinical study conducted from December 5, 2020, to October 8, 2021. Following a 14-day run-in period with an artificial tear administered 2 times per day, eligible participants were randomly assigned 1:1 to the treatment groups. Patients with moderate to severe DED were included in the study. INTERVENTIONS: Cyclosporine solution vs vehicle administered 2 times per day for 29 days. MAIN OUTCOMES AND MEASURES: The primary end points were changes from baseline in total corneal fluorescein staining (tCFS; 0-15 National Eye Institute scale) and in dryness score (0-100 visual analog scale) at day 29. Conjunctival staining, central corneal fluorescein staining, and tCFS responders were also assessed. RESULTS: A total of 834 study participants were randomly assigned to cyclosporine (423 [50.7%]) or vehicle (411 [49.3%]) groups at 27 sites. Participants had a mean (SD) age of 57.1 (15.8) years, and 609 (73.0%) were female individuals. The majority of participants self-identified in the following race categories: 79 Asian (9.5 %), 108 Black (12.9%), and 635 White (76.1%). Participants treated with cyclosporine solution had greater improvement in tCFS (-4.0 grades) than the vehicle group (-3.6 grades) at day 29 (change [∆] = -0.4; 95% CI, -0.8 to 0; P = .03). The dryness score showed treatment benefits from baseline in both groups: -12.2 points for cyclosporine and -13.6 points for vehicle (∆ = 1.4; 95% CI, -1.8 to 4.6; P = .38). In the cyclosporine group, 293 participants (71.6%) achieved clinically meaningful reductions of 3 grades or higher in tCFS vs 236 (59.7%) in the vehicle group (∆ = 12.6%; 95% CI, 6.0%-19.3%; P < .001). These responders showed greater improvement in symptoms at day 29 including dryness (∆ = -4.6; 95% CI, -8.0 to -1.2; P = .007) and blurred vision (Δ = -3.5; 95% CI, -6.6 to -4.0; P = .03) compared with nonresponders. CONCLUSIONS AND RELEVANCE: The ESSENCE-2 trial confirmed that treatment with a water-free cyclosporine solution, 0.1%, results in early therapeutic effects on the ocular surface compared with vehicle. The responder analyses suggest that the effect is clinically meaningful in 71.6% of participants in the cyclosporine group. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04523129.
引用
- Akpek EK, Wirta DL, Downing JE, et al. Efficacy and Safety of a Water-Free Topical Cyclosporine, 0.1%, Solution for the Treatment of Moderate to Severe Dry Eye Disease: The ESSENCE-2 Randomized Clinical Trial. JAMA Ophthalmol. 2023. PMID: 37022717. doi:10.1001/jamaophthalmol.2023.0709
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。